Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Nov 11 - Nov 16
Enhances satiety and energy balance: GIP action in the CNS contributes to reduced food intake and weight loss 1,2,3
The PSA and the cost-effectiveness acceptability curves suggested that subcutaneous tirzepatide had a larger potential of being cost-effective when compared with oral semaglutide, with a 97.8% probability at a WTP of $150,000 per QALY at 68 weeks
Average weight loss hides how many people actually hit meaningful thresholds, so the trials also report the share of participants reaching 5%, 10%, 15%, and 20% body-weight reductions
When administered subcutaneously once weekly, tirzepatide binds to both GIP and GLP-1 receptors, triggering multiple physiological responses
US$ 24.45
US$ 20.84
US$ 20.64
US$ 26.60
US$ 29.62
